[1. D’Angelo E, Prat J. Uterine sarcoma: a review. Gynecol Oncol. 2010; 116:131-9.10.1016/j.ygyno.2009.09.023]Open DOISearch in Google Scholar
[2. Wilailak S, Tansuttiwong A, Tangtrakul S. Uterine sarcomas in Ramathibodi hospital (1987-1998). Thai J Obstet Gynecol. 2000; 12:241-6.]Search in Google Scholar
[3. Tavassoli FA, Davilee P, eds. World Health Organization classification of Tumours: Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.]Search in Google Scholar
[4. FIGO Committee on Gynecologic Oncology. FIGO staging for uterine sarcomas. Int J Gynecol Obstet. 2009; 104:179.10.1016/j.ijgo.2008.12.009]Search in Google Scholar
[5. FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet. 2009; 105:103-4.10.1016/j.ijgo.2009.02.012]Search in Google Scholar
[6. Sandra EB, Min Z, Timonthy C, Claudia RB. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gyneoncol Oncol. 2004; 93:204-8.10.1016/j.ygyno.2003.12.029]Search in Google Scholar
[7. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 2002; 12:687-90.10.1046/j.1525-1438.2002.01151.x]Open DOISearch in Google Scholar
[8. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol. 2008; 134:1277-87.10.1007/s00432-008-0422-2]Search in Google Scholar
[9. Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki university central hospital 1990-2001. Gynecol Oncol. 2008; 111: 74-81.10.1016/j.ygyno.2008.06.002]Open DOISearch in Google Scholar
[10. Sutton G, Kavanagh J, Wolfson A, Tornos C. Corpus: mesenchymal tumors. In: Hoskin WJ, Perez CA, Young RC, Barakat RR, Markman M, Randall ME, eds. Principles and practice of gynecologic oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 873-94.]Search in Google Scholar
[11. Meredith RF, Elsert DR, Kaka Z, Hodgson SE, Johnston GA, Boutselis JG. An excess of uterine sarcomas after pelvic radiation. Cancer. 1986; 58:2003-7.10.1002/1097-0142(19861101)58:9<2003::AID-CNCR2820580908>3.0.CO;2-2]Open DOISearch in Google Scholar
[12. Lavie O, Barnett O, Narod SA, Rennert G. The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer. 2008; 18:352-6.10.1111/j.1525-1438.2007.01025.x]Open DOISearch in Google Scholar
[13. Buchanan EM, Weinstein LC, Hillson C. Endometrial Cancer. Am Fam Physician. 2009; 80:1075-80.]Search in Google Scholar
[14. Sirisabya N, Manchana T, Worasethsin P, Khemapech N, Lertkhachonsuk R, Sittisomwong T, et al . Is complete surgical staging necessary in clinically early stage endometrial carcinoma? Int J Gynecol Cancer. 2009; 19: 1057-61.10.1111/IGC.0b013e3181a8ba85]Open DOISearch in Google Scholar
[15. Zivanovic O, Leitao MM, Iasonos A, Jacks LM, Zhou Q, Abu-Rustum NR, et al. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer staging systems. J Clin Oncol. 2009; 27:2066-72.10.1200/JCO.2008.19.8366]Open DOISearch in Google Scholar
[16. Raut CP, Nucci MR, Wang Q, Manolac J, Bertagnollia MM, Demetrid GD, et al. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer. 2009; 45:2818-24.10.1016/j.ejca.2009.06.030]Open DOISearch in Google Scholar
[17. Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol. 2009; 10:1188-98.10.1016/S1470-2045(09)70226-8]Open DOISearch in Google Scholar
[18. Nam JH, Park JY. Update on treatment of uterine sarcoma. Curr Opin Obstet Gynecol. 2010; 22:36-42.10.1097/GCO.0b013e328334d90f19923988]Open DOISearch in Google Scholar
[19. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008; 112:820-30.10.1002/cncr.2324518189292]Open DOISearch in Google Scholar
[20. Chan JK, Kawar NM, Shin JY, Osann K, Chen LM, Powell CB, et al. Endometrial stromal sarcoma: a population-based study. Br J Cancer. 2008; 99:1210-15.10.1038/sj.bjc.6604527257050318813312]Open DOISearch in Google Scholar
[21. Amant F, De Knijf A, Van Calster B, Leunen1 K, Neven1 P, Berteloot P, et al. Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br J Cancer. 2007; 9:1194-9.10.1038/sj.bjc.6603986236046617895898]Search in Google Scholar
[22. Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Onco.l 2008; 111:82-8.10.1016/j.ygyno.2008.05.01618674808]Open DOISearch in Google Scholar
[23. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as postsurgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007; 107:177-85.10.1016/j.ygyno.2007.07.070275233117822748]Open DOISearch in Google Scholar
[24. Denschlag D, Masoud I, Stanimir G, Gilbert L. Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol. 2007; 33:91-5.10.1016/j.ejso.2006.11.01217174517]Open DOISearch in Google Scholar